200 related articles for article (PubMed ID: 19153363)
1. Lipoatrophy associated with interferon alfa adjuvant therapy for melanoma.
Vallés L; González M; Polo I; Enguita AB; Vanaclocha F; Ortiz-Romero PL
Arch Dermatol; 2009 Jan; 145(1):98-9. PubMed ID: 19153363
[No Abstract] [Full Text] [Related]
2. Early signs of liver failure after low-dose interferon alfa-2b for cutaneous melanoma.
Ammoury A; El Sayed F; Farah C; Bazex J
J Am Acad Dermatol; 2008 Mar; 58(3):532-3. PubMed ID: 18280369
[No Abstract] [Full Text] [Related]
3. Delayed wound healing following treatment with low-dose interferon alfa-2b for cutaneous melanoma.
Ammoury AF; El Sayed F; Bazex J
Arch Dermatol; 2007 Oct; 143(10):1339-40. PubMed ID: 17938359
[No Abstract] [Full Text] [Related]
4. Livedo reticularis associated with interferon alpha therapy in two melanoma patients.
Ruiz-Genao DP; García-F-Villalta MJ; Hernández-Núñez A; Ríos-Buceta L; Fernández-Herrera J; García-Díez A
J Eur Acad Dermatol Venereol; 2005 Mar; 19(2):252-4. PubMed ID: 15752306
[TBL] [Abstract][Full Text] [Related]
5. Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b.
Moschos SJ; Kirkwood JM; Konstantinopoulos PA
J Clin Oncol; 2004 Jan; 22(1):11-4. PubMed ID: 14665613
[No Abstract] [Full Text] [Related]
6. Nursing management of patients with malignant melanoma receiving adjuvant alpha interferon-2b.
Kiley KE; Gale DM
Clin J Oncol Nurs; 1998 Jan; 2(1):11-6. PubMed ID: 9481251
[TBL] [Abstract][Full Text] [Related]
7. [Ocular complications of adjuvant interferon therapy for malignant melanoma: a review].
Ockenfels M; Lisch W
Hautarzt; 2003 Feb; 54(2):144-7. PubMed ID: 12590309
[TBL] [Abstract][Full Text] [Related]
8. Grand mal seizure induced by interferon-alpha-2b.
Kors C; Milling A; Hofmann M; Sterry W; Trefzer U
J Eur Acad Dermatol Venereol; 2006 Apr; 20(4):473-4. PubMed ID: 16643159
[No Abstract] [Full Text] [Related]
9. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
Eggermont AM; Suciu S; MacKie R; Ruka W; Testori A; Kruit W; Punt CJ; Delauney M; Sales F; Groenewegen G; Ruiter DJ; Jagiello I; Stoitchkov K; Keilholz U; Lienard D;
Lancet; 2005 Oct; 366(9492):1189-96. PubMed ID: 16198768
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant interferon alfa-2b for high-risk melanoma.
Retsas S
J Clin Oncol; 1996 Jun; 14(6):1968-9. PubMed ID: 8656272
[No Abstract] [Full Text] [Related]
12. Cutaneous sarcoidosis by interferon therapy in a patient with melanoma.
Alonso-Pérez A; Ballestero-Díez M; Fraga J; García-Díez A; Fernández-Herrera J
J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1328-9. PubMed ID: 17062055
[No Abstract] [Full Text] [Related]
13. Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial.
Hauschild A; Weichenthal M; Rass K; Linse R; Berking C; Böttjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Stein A; Näher H; Schadendorf D; Mohr P; Kaatz M; Tronnier M; Hein R; Schuler G; Egberts F; Garbe C
J Clin Oncol; 2010 Feb; 28(5):841-6. PubMed ID: 20048184
[TBL] [Abstract][Full Text] [Related]
14. Livedo reticularis: a side effect of interferon therapy in a pediatric patient with melanoma.
Fox M; Tahan S; Kim CC
Pediatr Dermatol; 2012; 29(3):333-5. PubMed ID: 21575046
[TBL] [Abstract][Full Text] [Related]
15. Comment on "Perhaps not everyone knows that...", (Ann Oncol 2001; 12: 1186).
Sulkes A; Schachter J
Ann Oncol; 2002 Apr; 13(4):637. PubMed ID: 12056717
[No Abstract] [Full Text] [Related]
16. Meyerson's phenomenon in a patient affected by high-risk melanoma under treatment with interferon-α.
Zonta E; Chiarion V; Zarian H; Peserico A; Alaibac M
Melanoma Res; 2012 Jun; 22(3):284-5. PubMed ID: 22543678
[No Abstract] [Full Text] [Related]
17. Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analyses.
Creagan ET; Ahmann DL; Frytak S; Long HJ; Chang MN; Itri LM
Cancer; 1987 Feb; 59(3 Suppl):638-46. PubMed ID: 10822463
[TBL] [Abstract][Full Text] [Related]
18. [Recombinant interferon alfa-2b in the treatment of patients with skin melanoma].
Korovin SI
Lik Sprava; 1998; (2):139-41. PubMed ID: 9670687
[TBL] [Abstract][Full Text] [Related]
19. [Interferons and malignant melanoma].
Dreno B
Rev Med Interne; 2002 Nov; 23 Suppl 4():489s-493s. PubMed ID: 12481404
[TBL] [Abstract][Full Text] [Related]
20. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis.
Hauschild A; Weichenthal M; Balda BR; Becker JC; Wolff HH; Tilgen W; Schulte KW; Ring J; Schadendorf D; Lischner S; Burg G; Dummer R
J Clin Oncol; 2003 Aug; 21(15):2883-8. PubMed ID: 12885805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
